1037794-22-1

Basic information

• Product Name: (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide
• Synonyms: (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide
• CAS NO: 1037794-22-1
• Molecular Weight: 280.327
• Mol File: 1037794-22-1.mol

Chemical Properties

• CAS DataBase Reference: (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide(1037794-22-1)
• EPA Substance Registry System: (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide(1037794-22-1)

Safety Data

• Hazardous Substances Data: 1037794-22-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide is used as a potential therapeutic agent for its possible interactions with biological targets in the body. (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide's unique structure may allow it to engage with specific receptors or enzymes, potentially leading to novel treatments for various medical conditions.
Used in Biochemical Research:
In the field of biochemistry, (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide serves as a valuable compound for studying its interactions with different biological molecules. This research could provide insights into new pathways or targets for drug development, contributing to the advancement of medical knowledge and the creation of innovative therapies.

Upstream product

• 870487-04-0 (S)-(9H-fluoren-9-yl)methyl (1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)carbamate 
• 623-04-1 4-aminobenzenemethanol 
• 133174-15-9 (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-ureidopentanoic acid 
• 372-75-8 Citrulline 
• 1037793-80-8 (S)-tert-butyl 1-(4-(hydroxymethyl)phenylamino)-1-oxo-5-ureidopentan-2-ylcarbamate 
• 110-89-4 piperidine 
• 6692-89-3 N^α-benzyloxy-carbonyl-L-citrulline 

Downstream Products

• 1037794-26-5 Fmoc-Cit-PABOH 
• 1608127-09-8 C₂₂H₃₃N₅O₆ 
• 1608127-10-1 C₅₀H₆₀N₆O₁₈ 
• 1022094-34-3 C₄₆H₅₆N₆O₁₆ 
• 159857-79-1 (2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-N-[4-(hydroxymethyl)phenyl]-5-ureidopentanamide 

Relevant articles and documents

Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research

Antibody-drug conjugates (ADCs) represent an emerging class of biopharmaceutical agents that deliver highly potent anticancer agents (payloads) selectively to tumors or components associated with the tumor microenvironment. The linker, responsible for the connection between the antibody and payload, is a crucial component of ADCs. In certain examples the linker is composed of a cleavable short peptide which imparts an additional aspect of selectivity. Especially prevalent is the cathepsin B cleavable Mc-Val-Cit-PABOH linker utilized in many pre-clinical ADC candidates, as well as the FDA approved ADC ADCETRIS (brentuximab vedotin). An alternative route for the synthesis of the cathepsin B cleavable Mc-Val-Cit-PABOH linker is reported herein that involved six steps from l-Citrulline and proceeded with a 50% overall yield. In this modified route, the spacer (a para-aminobenzyl alcohol moiety) was incorporated via HATU coupling followed by dipeptide formation. Importantly, this route avoided undesirable epimerization and proceeded with improved overall yield. Utilizing this methodology, a drug-linker construct incorporating a potent small-molecule inhibitor of tubulin polymerization (referred to as KGP05), was synthesized as a representative example.

A Wireframe DNA Cube: Antibody Conjugate for Targeted Delivery of Multiple Copies of Monomethyl Auristatin E

In recent years, several antibody drug conjugates (ADC) have been accepted by the FDA as therapeutics against cancer. It is well-known that control of drug-to-antibody ratio (DAR) is vital for the success of an ADC, which inspires the advancement of bette

BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF

The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity

Antibody-drug conjugates (ADCs) have become an important therapeutic modality for oncology, with three approved by the FDA and over 60 others in clinical trials. Despite the progress, improvements in ADC therapeutic index are desired. Peptide-based ADC linkers that are cleaved by lysosomal proteases have shown sufficient stability in serum and effective payload-release in targeted cells. If the linker can be preferentially hydrolyzed by tumor-specific proteases, safety margin may improve. However, the use of peptide-based linkers limits our ability to modulate protease specificity. Here we report the structure-guided discovery of novel, nonpeptidic ADC linkers. We show that a cyclobutane-1,1-dicarboxamide-containing linker is hydrolyzed predominantly by cathepsin B while the valine-citrulline dipeptide linker is not. ADCs bearing the nonpeptidic linker are as efficacious and stable in vivo as those with the dipeptide linker. Our results strongly support the application of the peptidomimetic linker and present new opportunities for improving the selectivity of ADCs.

DRUG-LINKER CONJUGATE PHARMACEUTICAL COMPOSITIONS

Compositions are disclosed having a cytotoxic and/or vascular disrupting agent (VDA) payload attached to a linker. The linker can be a cathepsin B protease cleavable linker or a non-cleavable linker that may degrade intracellularly. Methods for making and using the compositions are also provided. The compositions can be provided to a patient in need thereof with the composition coming into contact with a cancer cell to activate or release the cytotoxic and/or vascular disrupting agent payload.

SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.